Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label active-controlled study of semaglutide injection in Chinese adults with obesity
ChiCTR2500097207Phase 3Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in obesity (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Body weight. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on ChiCTR2500097207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097207.